Fatty Liver Disease Symptoms: Signs of NAFLD/MASLD

Why is fatty liver disease often called a "silent" condition?

The liver is a resilient organ with a large reserve capacity. Fat accumulation in liver cells — the defining feature of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) — does not immediately impair the liver's function enough to cause obvious symptoms. Most people with MASLD feel entirely normal in the early stages.

This is why fatty liver disease is frequently discovered incidentally:

• Elevated AST or ALT on a routine blood panel
• A liver ultrasound ordered for another reason (like abdominal pain or gallstone evaluation) that notes a "bright" or "echogenic" liver — typical of fat
• Imaging for a different organ that includes the liver in the field of view

In 2023 an international multisociety consensus replaced the term NAFLD with MASLD to better reflect the metabolic underpinnings of the disease and to reduce stigma 1Ref 1Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, et al. (2023).AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.AASLD practice guidance covering MASLD diagnosis, cardiometabolic risk assessment, and the rationale for non-invasive evaluation in primary care. Because MASLD is closely linked to obesity, type 2 diabetes, and metabolic syndrome, it is one of the more common liver conditions seen in primary care 1Ref 1Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, et al. (2023).AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.AASLD practice guidance covering MASLD diagnosis, cardiometabolic risk assessment, and the rationale for non-invasive evaluation in primary care2Ref 2National Institute of Diabetes and Digestive and Kidney Diseases (2023).Definition & Facts of NAFLD & NASH.Patient-facing overview of NAFLD/MASLD prevalence, risk factors, and typical presentation including the silent nature of early disease.

What symptoms can fatty liver disease cause?

When symptoms do occur, they are often vague and easy to attribute to other causes:

Fatigue Persistent tiredness is one of the most commonly reported symptoms in people with MASLD. It tends to be unrefreshing — not improved by rest. The mechanism is not fully understood.

Right upper quadrant discomfort A dull ache, pressure, or sense of fullness in the upper right side of the abdomen — where the liver sits — is reported by some people. This is not a sharp or severe pain in uncomplicated fatty liver.

Abdominal bloating or general heaviness Some people describe a general sense of fullness or bloating.

No symptoms at all This remains the most common scenario, particularly in early disease 2Ref 2National Institute of Diabetes and Digestive and Kidney Diseases (2023).Definition & Facts of NAFLD & NASH.Patient-facing overview of NAFLD/MASLD prevalence, risk factors, and typical presentation including the silent nature of early disease.

Symptoms that signal more advanced disease

As fatty liver progresses to inflammation (MASH — metabolic dysfunction-associated steatohepatitis) and then to fibrosis and cirrhosis, more noticeable and serious symptoms can develop:

• Jaundice — yellowing of the skin or whites of the eyes
• Swelling of the abdomen from fluid accumulation (ascites)
• Swelling of the legs and ankles (edema)
• Easy bruising or bleeding
• Spider angiomas — small, spider-like blood vessels visible on the skin
• Mental confusion or difficulty concentrating (hepatic encephalopathy at advanced stages)

These symptoms signal significant liver dysfunction and require prompt medical evaluation. They are not typical of simple fatty liver — they suggest fibrosis or cirrhosis 2Ref 2National Institute of Diabetes and Digestive and Kidney Diseases (2023).Definition & Facts of NAFLD & NASH.Patient-facing overview of NAFLD/MASLD prevalence, risk factors, and typical presentation including the silent nature of early disease3Ref 3Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ (2023).AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.Non-invasive fibrosis assessment tools (FIB-4, elastography) and their role in stratifying MASLD patients; signs of advanced fibrosis/cirrhosis.

Who is at highest risk for fatty liver disease?

MASLD is closely linked to metabolic health. People at elevated risk include those with:

• Obesity — particularly abdominal (central) obesity
• Type 2 diabetes or insulin resistance
• High triglycerides or low HDL cholesterol
• Metabolic syndrome (a combination of the above)
• Hypothyroidism or other hormonal conditions

Even people without obesity can develop MASLD — lean NAFLD is recognized as a distinct presentation, particularly in people of East Asian descent. The AASLD practice guidance recommends assessing all patients with MASLD for cardiometabolic risk factors, because cardiovascular disease is a leading cause of death in this population 1Ref 1Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, et al. (2023).AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.AASLD practice guidance covering MASLD diagnosis, cardiometabolic risk assessment, and the rationale for non-invasive evaluation in primary care.

How is fatty liver disease evaluated and followed?

A blood panel — including liver enzymes (AST, ALT), a lipid panel, and blood glucose or HbA1c — combined with a liver ultrasound can provide a strong initial picture without any invasive testing. Non-invasive fibrosis scores (such as FIB-4 or vibration-controlled transient elastography) help identify patients who need further evaluation 3Ref 3Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ (2023).AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.Non-invasive fibrosis assessment tools (FIB-4, elastography) and their role in stratifying MASLD patients; signs of advanced fibrosis/cirrhosis.

If initial tests suggest more advanced disease, your clinician can refer you to a gastroenterologist or hepatologist. Fatty liver identified before significant fibrosis develops has a much better prognosis. Gale's primary care clinicians can evaluate your risk factors, order appropriate tests, and guide next steps.